StockMacro
Menu

Viatris

$19.63 +21% in 6 monthsMarket cap $22.5B

VTRS on XNAS, Health Care, Viatris Inc., job postings

Measures activity, not value. Not investment advice.

Shares rose 93% in a year while the company posted a 12-month net loss of $607.8M.

  • WatchTwelve-month revenue up 4.3% to $14.7B, but quarterly revenue slipped 0.3%

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

Industry
Pharmaceutical preparations (Health Care)
Employees
30,000
Website
viatris.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.7B, net loss $325.3M.
Quarter to 31 Dec 2021: revenue $4.3B, net income –Quarter to 31 Mar 2022: revenue $4.2B, net income $399.2MQuarter to 31 Mar 2022: revenue $4.2B, net income $399.2MQuarter to 30 Jun 2022: revenue $4.1B, net income $313.9MQuarter to 30 Jun 2022: revenue $4.1B, net income $313.9MQuarter to 30 Sep 2022: revenue $4.1B, net income $354.3MQuarter to 30 Sep 2022: revenue $4.1B, net income $354.3MQuarter to 31 Dec 2022: revenue $3.9B, net income –Quarter to 31 Mar 2023: revenue $3.7B, net income $224.7MQuarter to 31 Mar 2023: revenue $3.7B, net income $224.7MQuarter to 30 Jun 2023: revenue $3.9B, net income $264.0MQuarter to 30 Jun 2023: revenue $3.9B, net income $264.0MQuarter to 30 Sep 2023: revenue $3.9B, net income $331.6MQuarter to 30 Sep 2023: revenue $3.9B, net income $331.6MQuarter to 31 Dec 2023: revenue $3.8B, net income –Quarter to 31 Mar 2024: revenue $3.7B, net income $113.9MQuarter to 31 Mar 2024: revenue $3.7B, net income $113.9MQuarter to 30 Jun 2024: revenue $3.8B, net income -$326.4MQuarter to 30 Jun 2024: revenue $3.8B, net income -$326.4MQuarter to 30 Sep 2024: revenue $3.8B, net income $94.8MQuarter to 30 Sep 2024: revenue $3.8B, net income $94.8MQuarter to 31 Dec 2024: revenue $3.5B, net income –Quarter to 31 Mar 2025: revenue $3.3B, net income -$3.0BQuarter to 31 Mar 2025: revenue $3.3B, net income -$3.0BQuarter to 30 Jun 2025: revenue $3.6B, net income -$4.6MQuarter to 30 Jun 2025: revenue $3.6B, net income -$4.6MQuarter to 30 Sep 2025: revenue $3.8B, net income -$128.2MQuarter to 30 Sep 2025: revenue $3.8B, net income -$128.2MQuarter to 31 Dec 2025: revenue $3.7B, net income –Quarter to 31 Mar 2026: revenue $3.5B, net income $176.4MQuarter to 31 Mar 2026: revenue $3.5B, net income $176.4MQuarter to 30 Jun 2026: revenue $3.8B, net income -$118.8MQuarter to 30 Jun 2026: revenue $3.8B, net income -$118.8MQuarter to 30 Sep 2026: revenue $3.7B, net income -$325.3MQuarter to 30 Sep 2026: revenue $3.7B, net income -$325.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $4.3B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$3.7B-$325.3M
30 Jun 2026$3.8B-$118.8M
31 Mar 2026$3.5B$176.4M
31 Dec 2025$3.7B–
30 Sep 2025$3.8B-$128.2M
30 Jun 2025$3.6B-$4.6M
31 Mar 2025$3.3B-$3.0B
31 Dec 2024$3.5B–
30 Sep 2024$3.8B$94.8M
30 Jun 2024$3.8B-$326.4M
31 Mar 2024$3.7B$113.9M
31 Dec 2023$3.8B–
30 Sep 2023$3.9B$331.6M
30 Jun 2023$3.9B$264.0M
31 Mar 2023$3.7B$224.7M
31 Dec 2022$3.9B–
30 Sep 2022$4.1B$354.3M
30 Jun 2022$4.1B$313.9M
31 Mar 2022$4.2B$399.2M
31 Dec 2021$4.3B–
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $14.7B $14.1B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +4.3% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$607.8M -$3.7B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.53 -$3.09
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 35.3% 36.0% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -0.0% -18.8% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -4.1% -26.1% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -4.2% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $2.1B –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.8B $975.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $13.3B $14.4B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $11.5B $13.5B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.97 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $11.94
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.5 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.3 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.6 2.0
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 2.4% 2.5%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ViatrisVTRS (this company) $22.5Bloss1.5+4.3%-4.1%
United TherapeuticsUTHR $23.6B19.27.4+1.9%38.6%
Alnylam PharmaceuticalsALNY $19.3B7.3–––
Roivant SciencesROIV $28.0Bloss682–-838%
Royalty PharmaRPRX $30.5B45.411.6+11%25.7%
InsmedINSM $31.0Bloss20.4+240%-39.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+2.2%

1,026 13F filers vs 1,004

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

89%

1.0B shares held by 13F filers (30 Sep 2026) of 1.1B outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

3.1%

35.2M shares sold short (30 Oct 2026) of 1.1B outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.0

35.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-7.1%

37.9M shares sold short in the report before, 35.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

46%

46% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

30K

reported for the year to 31 Dec 2025

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-0.3%

$3.7B vs $3.8B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-1.3%

$85.7M vs $86.8M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$2.0M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

35

35 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.8×

35 articles in the last 7 days; its usual week has 4.

Price $19.63 on 20 Nov 2026, +93% over 12 months (12-month range $10.19 to $21.06)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $1.1M in the last 12 months (the 12 months before: $684K).
Revenue per quarter. Revenue $3.7B in the latest quarter, -0.3% on a year earlier.
Capital spending per quarter. Capital spending $85.7M in the latest quarter, -1.3% on a year earlier.
Institutional holders (13F filers). 1,026 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Federal obligations. Federal obligations: -$0.0 published in the last 12 months (none in the 12 months before).
Lobbying spend. Lobbying spend: $2.0M published in the last 12 months, -19% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 20268-K and other filingsCompleted acquisition of Pacira BioSciences for $36.50 per share in cash, about $1.7B aggregate, closed Nov 17, 2026
4 May 20268-K and other filingsDirector or officer change
26 Feb 20268-K and other filingsRestructuring costs announced
3 Feb 20268-K and other filingsDirector or officer change
3 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Aug 20258-K and other filingsDirector or officer change
5 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 May 20258-K and other filingsDirector or officer change
5 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Apr 2025Lobbying filingnew lobbying registration (S-3 GROUP)
22 Jan 2025Sharp changeLobbying on a new issue: lobbying on a new issue: DEF (2024-12-31)
21 Jan 2025Lobbying filinglobbying engagement terminated (WEST FRONT STRATEGIES LLC)
6 Dec 20248-K and other filingsDirector or officer change
6 Dec 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Jul 20248-K and other filingsCompleted an acquisition or asset sale
3 Jun 20248-K and other filingsDirector or officer change
3 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Dec 20238-K and other filingsDirector or officer change
20 Oct 20238-K and other filingsDirector or officer change
20 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Oct 2023Lobbying filinglobbying engagement terminated (RAMPY NORTHRUP LLC)
22 May 20238-K and other filingsDirector or officer change
27 Feb 20238-K and other filingsDirector or officer change
29 Dec 20228-K and other filingsDirector or officer change
29 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Nov 20228-K and other filingsCompleted an acquisition or asset sale
20 Oct 2022Sharp changeLobbying on a new issue: lobbying on a new issue: VET (2022-09-30)
1 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 197.4M vs usual 49.5M (2021-12-31); 1.7x the same period a year earlier
21 Jan 2022Sharp changeLobbying on a new issue: lobbying on a new issue: FIN, LBR, PHA, TAX (2021-12-31)
20 Jan 2022Lobbying filinglobbying engagement terminated (THEGROUP DC, LLC)
Insider net buying (open market)
Month from 1 Mar 2022: -$4.6M published
Month from 1 May 2022: -$106K published
Month from 1 Aug 2022: -$100K published
Month from 1 Nov 2022: -$140K published
Month from 1 Mar 2023: -$128K published
Month from 1 Nov 2023: -$140K published
Month from 1 Dec 2023: -$42K published
Month from 1 Jan 2024: -$46K published
Month from 1 Feb 2024: -$104K published
Month from 1 Mar 2024: -$3.8M published
Month from 1 May 2024: -$928K published
Month from 1 Jun 2024: -$3.6M published
Month from 1 Aug 2024: -$4.7M published
Month from 1 Sep 2024: -$2.3M published
Month from 1 Oct 2024: $61K published
Month from 1 Nov 2024: -$347K published
Month from 1 May 2025: $536K published
Month from 1 Aug 2025: $220K published
Month from 1 Sep 2025: -$72K published
Month from 1 Mar 2026: -$278K published
Month from 1 Jun 2026: -$810K published
Revenue per quarter
Quarter ended 31 Dec 2021: $4.3B, +20% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $4.2B, -5.4% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $4.1B, -10% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $4.1B, -10% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $3.9B, -11% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $3.7B, -11% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $3.9B, -4.8% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $3.9B, -3.3% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $3.8B, -1.0% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $3.7B, -1.8% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $3.8B, -3.1% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $3.8B, -4.8% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $3.5B, -8.1% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $3.3B, -11% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $3.6B, -5.6% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $3.8B, +0.2% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $3.7B, +5.0% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $3.5B, +8.1% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $3.8B, +4.9% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $3.7B, -0.3% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $197.4M, +69% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $64.5M, +30% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $83.9M, -6.0% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $103.9M, -14% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $153.7M, -22% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $47.8M, -26% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $67.8M, -19% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $95.9M, -7.7% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $165.5M, +7.7% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $49.8M, +4.2% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $58.8M, -13% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $77.0M, -20% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $140.4M, -15% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $42.6M, -14% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $52.9M, -10% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $86.8M, +13% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $196.5M, +40% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $39.9M, -6.3% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $52.8M, -0.2% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $85.7M, -1.3% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 930; public on 14 Feb 2022
31 Mar 2022 report: 945; public on 16 May 2022
30 Jun 2022 report: 925; public on 15 Aug 2022
30 Sep 2022 report: 877; public on 14 Nov 2022
31 Dec 2022 report: 908; public on 14 Feb 2023
31 Mar 2023 report: 903; public on 15 May 2023
30 Jun 2023 report: 881; public on 14 Aug 2023
30 Sep 2023 report: 866; public on 14 Nov 2023
31 Dec 2023 report: 925; public on 14 Feb 2024
31 Mar 2024 report: 940; public on 15 May 2024
30 Jun 2024 report: 934; public on 14 Aug 2024
30 Sep 2024 report: 932; public on 14 Nov 2024
31 Dec 2024 report: 970; public on 14 Feb 2025
31 Mar 2025 report: 947; public on 15 May 2025
30 Jun 2025 report: 918; public on 14 Aug 2025
30 Sep 2025 report: 917; public on 14 Nov 2025
31 Dec 2025 report: 960; public on 17 Feb 2026
31 Mar 2026 report: 990; public on 15 May 2026
30 Jun 2026 report: 1,004; public on 14 Aug 2026
30 Sep 2026 report: 1,026; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2022: -$2.5 published
Month from 1 Dec 2025: -$0.0 published
Month from 1 Apr 2026: -$0.0 published
Lobbying spend
Quarter from 1 Jan 2022: $630K published
Quarter from 1 Apr 2022: $670K published
Quarter from 1 Jul 2022: $680K published
Quarter from 1 Oct 2022: $830K published
Quarter from 1 Jan 2023: $650K published
Quarter from 1 Apr 2023: $690K published
Quarter from 1 Jul 2023: $780K published
Quarter from 1 Oct 2023: $720K published
Quarter from 1 Jan 2024: $620K published
Quarter from 1 Apr 2024: $630K published
Quarter from 1 Jul 2024: $770K published
Quarter from 1 Oct 2024: $640K published
Quarter from 1 Jan 2025: $510K published
Quarter from 1 Apr 2025: $650K published
Quarter from 1 Jul 2025: $650K published
Quarter from 1 Oct 2025: $700K published
Quarter from 1 Jan 2026: $550K published
Quarter from 1 Apr 2026: $550K published
Quarter from 1 Jul 2026: $420K published
Quarter from 1 Oct 2026: $510K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is workers named in WARN notices at 80 (21 Aug 2017), 15% below its normal reading of 94.
  • Insider net buying (open market): Insiders sold a net $1.1M in the last 12 months (the 12 months before: $684K).
  • Revenue per quarter: Revenue $3.7B in the latest quarter, -0.3% on a year earlier.
  • Capital spending per quarter: Capital spending $85.7M in the latest quarter, -1.3% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 33 insider trades

No trades in the last 90 days; the latest was filed 26 Jun 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
26 Jun 2026Paul CampbellSee RemarksSellplanned in advance (10b5-1)50,076$16.17$810KForm 4
24 Mar 2026Paul CampbellSee RemarksSell21,350$13.28$284KForm 4
10 Mar 2026David S SimmonsDirectorBuy499$10.42$5KForm 4
12 Sep 2025Corinne Le GoffChief Commercial OfficerSellplanned in advance (10b5-1)7,032$10.25$72KForm 4
13 Aug 2025Scott Andrew SmithChief Executive OfficerBuy22,000$9.99$220KForm 4
14 May 2025Scott Andrew SmithChief Executive OfficerBuy60,000$8.94$536KForm 4
12 Nov 2024Paul CampbellSee RemarksSell26,925$12.88$347KForm 4
25 Oct 2024Harry KormanDirectorBuy4,403$13.91$61KForm 4

1,026 institutions reported shares at the end of Q3 2026, 89% of the shares outstanding; 92 opened a position, 82 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)133.6M11.7%$2.4B+36.9M+38%
BlackRock, Inc.85.2M7.43%$1.5B-795K-0.9%
Vanguard Capital Management LLC75.2M6.56%$1.3B-864K-1.1%
Davis Selected Advisers72.4M6.32%$1.3B-2.8M-3.8%
T. Rowe Price Associates Inc58.7M5.12%-9.5M-14%
Vanguard Portfolio Management LLC54.3M4.74%$962.3M+22K0%
State Street Corp46.4M4.05%$821.8M-6.7M-13%
Rubric Capital Management LP36.0M3.14%$637.9M+1.8M+5.4%
Geode Capital Management, LLC33.0M2.88%$584.6M+237K+0.7%
Invesco Ltd.22.0M1.92%$390.7M+1.3M+6.1%

Company events

All 33 company events

In 12 months: 3 major agreements, 2 director or officer changes, 1 restructuring, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
17 Nov 2026Completed acquisition of Pacira BioSciences for $36.50 per share in cash, about $1.69B aggregate, closed Nov 17, 20268-K
8 Oct 2026Signed a major agreement8-K
1 Jul 2026Signed a major agreementSame filing: took on new debt8-K
18 Jun 2026Signed a major agreementSame filing: took on new debt8-K
4 May 2026Director or officer change8-K
26 Feb 2026Restructuring costs announced8-K
3 Feb 2026Director or officer change8-K
5 Aug 2025Director or officer change8-K

Reported lobbying spend: $510K in Q3 2026, $420K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Feb 2025NewS-3 Groupfor Viatris (Mylan, Inc)Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug TestingHealth issuesFiling
31 Dec 2024EndedWest Front Strategies LLCfor Viatris IncIssues related to e-labeling.; Issues related to drug pricing; issues related to pharmaceutical supply chain; issues related to modernization of prescribing information for physicians and pharmacists; Improved Access to Affordable Medications Act, S. 1120; Increasing Transparency in Generic Drug Applications, S.775 and HR 3839; P; Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023,; Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).Pharmacy, Health issues, Copyright/patents, BudgetFiling
30 Sep 2023EndedRampy Northrup LLCfor Viatris IncLegislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs. H.R.1503, Prescription Information Modernizati; Issues related to modernizing access to prescribing information.Health issues, BudgetFiling
7 Oct 2021EndedThegroup DC, LLCfor Viatris IncNot statedFiling
1 Sep 2021NewBlue Ridge Law & Policy, P.C.for Viatris Inc.Corporate governance issuesFinancial institutionsFiling
1 Aug 2021EndedLincoln Policy Groupfor Mylan Inc.Not statedFiling
1 Jan 2021EndedBlue Ridge Law & Policy, P.C.for Viatris Inc.Not statedFiling
1 Mar 2020NewHolland & Knight LLPfor Viatris IncDrug shortages, formulary tiering, National Defense Authorization Act (NDAA), biosimilar uptake, the consumer price index, generic drugs.PharmacyFiling

Layoff notices

All 2 layoff notices

No notice in 12 months; the latest is dated 24 Aug 2017. State WARN notices.

NoticeSiteWorkersJobs endSource
24 Aug 2017Meda PharmaceuticalsMacon County, IL801 Feb 2018closureNotice
1 Oct 2016Meda Pharmaceuticals, Inc.Somerset, NJ9431 Dec 2016Notice
Timeline

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026Filings record

    Completed acquisition of Pacira BioSciences for $36.50 per share in cash, about $1.7B aggregate, closed Nov 17, 2026

  2. 4 May 2026Filings record

    Director or officer change

  3. 11 Mar 2026Insiders record

    SIMMONS DAVID S (director) bought 499 shares of VTRS ($5,202) (dated 10 Mar 2026)

  4. 26 Feb 2026Filings record

    Restructuring costs announced

  5. 3 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 3 Feb 2026Filings record

    Director or officer change

  7. 14 Aug 2025Insiders record

    Smith Scott Andrew (Chief Executive Officer) bought 22,000 shares of VTRS ($219,780) (dated 13 Aug 2025)

  8. 5 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 5 Aug 2025Filings record

    Director or officer change

  10. 15 May 2025Insiders record

    Smith Scott Andrew (Chief Executive Officer) bought 60,000 shares of VTRS ($536,400) (dated 14 May 2025)

  11. 5 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 5 May 2025Filings record

    Director or officer change

  13. 21 Apr 2025Lobbying record

    VIATRIS (MYLAN, INC): new lobbying registration (S-3 GROUP) (dated 1 Feb 2025)

  14. 22 Jan 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['DEF']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6274585
  15. 21 Jan 2025Lobbying record

    VIATRIS INC: lobbying engagement terminated (WEST FRONT STRATEGIES LLC) (dated 31 Dec 2024)

  16. 6 Dec 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 6 Dec 2024Filings record

    Director or officer change

  18. 26 Oct 2024Insiders record

    KORMAN HARRY (director) bought 4,403 shares of VTRS ($61,256) (dated 25 Oct 2024)

  19. 3 Jul 2024Filings record

    Completed an acquisition or asset sale

  20. 3 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 3 Jun 2024Filings record

    Director or officer change

  22. 15 Dec 2023Filings record

    Director or officer change

  23. 20 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 20 Oct 2023Filings record

    Director or officer change

  25. 20 Oct 2023Lobbying record

    VIATRIS INC: lobbying engagement terminated (RAMPY NORTHRUP LLC) (dated 30 Sep 2023)

  26. 22 May 2023Filings record

    Director or officer change

  27. 27 Feb 2023Filings record

    Director or officer change

  28. 29 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 29 Dec 2022Filings record

    Director or officer change

  30. 29 Nov 2022Filings record

    Completed an acquisition or asset sale

  31. 20 Oct 2022Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['VET']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12629210
  32. 16 Mar 2022Insiders record

    CORNWELL W DON (director) bought 2,700 shares of VTRS ($26,730) (dated 15 Mar 2022)

  33. 16 Mar 2022Insiders record

    GOETTLER MICHAEL (Chief Executive Officer) bought 50,352 shares of VTRS ($496,974) (dated 15 Mar 2022)

  34. 1 Mar 2022Financials change

    spent $197.4M on capital projects in the quarter ended 31 Dec 2021, 1.7× the same quarter last year.

    Same quarter last year: $116.9M; its normal quarter is $49.5M.

    See the evidence
    This period
    $197.4M (the quarter ended 31 Dec 2021)
    Normal quarter (median of 7 earlier)
    $49.5M
    Typical spread (median absolute deviation)
    $11.3M
    How far from its usual level
    +8.8
    Same quarter last year
    $116.9M
    History used
    640 days
    2020-03-31: $43.4M2020-06-30: $44.5M2020-09-30: $38.2M2020-12-31: $116.9M2021-03-31: $49.5M2021-06-30: $89.3M2021-09-30: $121.0M2021-12-31: $197.4M
    the quarter ended 31 Dec 20217 earlier quartersnormal: $49.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 21 Jan 2022Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['FIN', 'LBR', 'PHA', 'TAX']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12635752
  36. 20 Jan 2022Lobbying record

    VIATRIS INC: lobbying engagement terminated (THEGROUP DC, LLC) (dated 7 Oct 2021)

  37. 9 Nov 2021Financials change

    spent $121.0M on capital projects in the quarter ended 30 Sep 2021, 3.2× the same quarter last year.

    Same quarter last year: $38.2M; its normal quarter is $47.0M.

    See the evidence
    This period
    $121.0M (the quarter ended 30 Sep 2021)
    Normal quarter (median of 6 earlier)
    $47.0M
    Typical spread (median absolute deviation)
    $6.2M
    How far from its usual level
    +8.1
    Same quarter last year
    $38.2M
    History used
    548 days
    2020-03-31: $43.4M2020-06-30: $44.5M2020-09-30: $38.2M2020-12-31: $116.9M2021-03-31: $49.5M2021-06-30: $89.3M2021-09-30: $121.0M
    the quarter ended 30 Sep 20216 earlier quartersnormal: $47.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  38. 20 Oct 2021Lobbying record

    MYLAN INC.: lobbying engagement terminated (LINCOLN POLICY GROUP) (dated 1 Aug 2021)

  39. 22 May 2021Insiders record

    CORNWELL W DON (director) bought 2,000 shares of VTRS ($31,410) (dated 21 May 2021)

  40. 11 May 2021Financials change

    reported revenue of $4.4B for the quarter ended 31 Mar 2021, 1.7× the same quarter last year.

    Same quarter last year: $2.6B; its normal quarter is $0.

    See the evidence
    This period
    $4.4B (the quarter ended 31 Mar 2021)
    Normal quarter (median of 8 earlier)
    $0
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +4400.1
    Same quarter last year
    $2.6B
    History used
    640 days
    2019-06-30: $02019-09-29: $02019-12-31: $02020-03-29: $02020-03-31: $2.6B2020-06-28: $02020-09-27: $02020-12-31: $3.6B2021-03-31: $4.4B
    the quarter ended 31 Mar 20218 earlier quartersnormal: $0

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

Showing the newest 40 of 92 entries; narrow the window or the kind of data to see older ones.

Not listed: 116 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001792044
Ticker
VTRS
Domain
viatris.com
Employer name
Meda Pharmaceuticals, Inc., Mylan Technologies Inc. (2 unverified)
Fein
03-0336833 (1 unverified)
Hq location
PA|CANONSBURG|15317 (1 unverified)
Lobbying client
mylan laboratories, viatris, viatris mylan
Name
Abbex AB, Acton Pharmaceuticals, Inc, Aculys Pharma, Inc, Agila Australasia Pty Ltd and 245 more
Uei
NEYRLCN7HME7, TZY5BKQHCF21
Wikidata
Q101983981
Wikipedia
Viatris
  • DOL H-1B labor condition applications and PERM certifications2 data points9 Mar 2026 to 9 Mar 2026
  • Federal lobbying disclosures (LDA)35 records, 276 data points30 Jun 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings9 records, 216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)112 records7 May 2020 to 17 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)551 data points31 Dec 2017 to 2 Nov 2026
  • SEC Form 4 insider transactions33 records, 120 data points18 Dec 2020 to 26 Jun 2026
  • FINRA short interest (twice monthly)425 data points30 Nov 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3020 data points17 Nov 2020 to 20 Nov 2026
  • USASpending.gov federal awards12 data points31 Oct 2022 to 14 Jan 2026
  • WARN layoff notices (state labor agencies)2 records, 6 data points26 Sep 2016 to 24 Aug 2017
  • Wikipedia pageviews2456 data points11 Dec 2019 to 20 Nov 2026